MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
Rhea-AI Summary
MAIA Biotechnology (NYSE American: MAIA) announced that the CEO and certain directors purchased approximately 182,445 shares of MAIA common stock in open-market trades between November 21 and 28, 2025 at an average price of $1.06 per share. Vlad Vitoc, chairman and CEO, purchased 94,300 shares at an average of $1.08, while directors Cristian Luput and Stan V. Smith purchased a combined 88,145 shares at an average of $1.04.
The company highlighted clinical progress for ateganosine in its Phase 2 THIO-101 trial, reporting a 38% response rate and 17.8 months overall survival to date.
Positive
- Insiders purchased 182,445 shares Nov 21–28, 2025
- Chairman/CEO bought 94,300 shares at $1.08 average
- Directors bought 88,145 shares at $1.04 average
- Phase 2 THIO-101: 38% response rate reported
Negative
- Phase 2 THIO-101 data described as "to date" (interim)
News Market Reaction
On the day this news was published, MAIA gained 1.69%, reflecting a mild positive market reaction. Argus tracked a peak move of +15.1% during that session. Argus tracked a trough of -15.1% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $892K to the company's valuation, bringing the market cap to $54M at that time. Trading volume was exceptionally heavy at 9.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with names like BTAI at -4.17%, CUE at -0.94%, PDSB at +1.0%, ARTV at +0.96%, and QNTM at -4.74%, suggesting MAIA’s reaction to insider purchases was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Market opportunity update | Positive | +2.2% | Outlined $50B immunotherapy market and Phase 3 THIO-104 initiation for ateganosine. |
| Dec 01 | Insider share purchases | Positive | +1.7% | CEO and directors bought 182,445 shares and reiterated Phase 2 THIO-101 results. |
| Nov 21 | SITC 2025 clinical data | Positive | +4.7% | Reported THIO-101 expansion enrollment and 17.8-month OS plus Phase 3 screening start. |
| Nov 20 | Conference presentation | Positive | -5.3% | CEO presented telomere-targeting efficacy and 38% response rate vs ~6% current options. |
| Oct 27 | Trial in Progress poster | Positive | +4.9% | Reported first five Part C THIO-101 patients and a safety profile consistent with earlier parts. |
Recent MAIA news has generally been positive clinical and strategic updates, often met with positive price reactions, though a conference presentation on telomere targeting saw a notable selloff despite constructive trial data.
Over the last few months, MAIA has repeatedly highlighted progress for ateganosine in NSCLC. Key updates included a Trial in Progress poster on Oct 27, 2025, Romanian enrollment and Fast Track commentary on Nov 20, 2025, SITC 2025 data with 17.8 months OS on Nov 21, 2025, and market-expansion framing plus a planned Phase 3 THIO-104 trial on Dec 10, 2025. The current insider-purchase news on Dec 1, 2025 fits a pattern of management emphasizing both clinical momentum and engagement via open-market buying.
Market Pulse Summary
This announcement details open-market purchases totaling 182,445 shares by MAIA’s CEO and directors at an average of $1.06, alongside reaffirmation of Phase 2 THIO-101 data showing a 38% response rate and 17.8 months overall survival in NSCLC. In recent months, MAIA has repeatedly highlighted ateganosine’s progress and initiated pivotal development. Investors may track future clinical readouts, additional insider activity, and regulatory milestones to contextualize these developments.
Key Terms
immunotherapies medical
Phase 2 medical
clinical trial medical
overall survival medical
non-small cell lung cancer medical
AI-generated analysis. Not financial advice.
CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was
Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of
“Along with my fellow MAIA Board members, we are pleased to report that we recently acquired shares of MAIA in the open market, reflecting our confidence in ateganosine’s ongoing clinical development,” said Dr. Vitoc. “With
“I firmly believe MAIA’s cancer-therapy platform can redefine the landscape of cancer research and treatment,” said Mr. Luput. “As a longtime investor, I believe the company’s strategic focus and scientific momentum position it to deliver significant value for shareholders in the years ahead,” added Mr. Smith.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
FAQ
How many MAIA (MAIA) shares did the CEO and directors buy in November 2025?
What average price did MAIA insiders pay for the November 2025 purchases?
What clinical results did MAIA cite for ateganosine in the Phase 2 THIO-101 trial?
When were the MAIA insider purchases disclosed?
Do the MAIA insider purchases guarantee clinical or commercial success for ateganosine?
